Review
doi: 10.1038/oby.2011.69.
Epub 2011 Apr 7.
Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies
Affiliations
- PMID: 21475141
- DOI: 10.1038/oby.2011.69
Item in Clipboard
Review
Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies
Obesity (Silver Spring).
2011 Jul.
Free article
No abstract available
Similar articles
-
Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?Clin Endocrinol (Oxf). 2007 Mar;66(3):456-7. doi: 10.1111/j.1365-2265.2007.02760.x. Clin Endocrinol (Oxf). 2007. PMID: 17302885 No abstract available.
-
End of the line for cannabinoid receptor 1 as an anti-obesity target?Nat Rev Drug Discov. 2008 Dec;7(12):961-2. doi: 10.1038/nrd2775. Nat Rev Drug Discov. 2008. PMID: 19043439
-
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.J Clin Psychopharmacol. 2013 Feb;33(1):118-20. doi: 10.1097/JCP.0b013e3182793843. J Clin Psychopharmacol. 2013. PMID: 23277241 Free PMC article. Clinical Trial. No abstract available.
-
The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.J Clin Pharm Ther. 2007 Jun;32(3):209-31. doi: 10.1111/j.1365-2710.2007.00817.x. J Clin Pharm Ther. 2007. PMID: 17489873 Review.
-
[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].J Pharm Belg. 2005;60(3):89-91. J Pharm Belg. 2005. PMID: 16252510 Review. French.
Cited by
-
Medial prefrontal cortex diclofenac-induced antinociception is mediated through GPR55, cannabinoid CB1, and mu-opioid receptors of this area and periaqueductal gray.Naunyn Schmiedebergs Arch Pharmacol. 2020 Mar;393(3):371-379. doi: 10.1007/s00210-019-01735-x. Epub 2019 Oct 22. Naunyn Schmiedebergs Arch Pharmacol. 2020. PMID: 31641818
-
Endocannabinoids in Body Weight Control.Pharmaceuticals (Basel). 2018 May 30;11(2):55. doi: 10.3390/ph11020055. Pharmaceuticals (Basel). 2018. PMID: 29849009 Free PMC article. Review.
-
Pharmacological Evaluation of Cannabinoid Receptor Modulators Using GRABeCB2.0 Sensor.Int J Mol Sci. 2024 May 3;25(9):5012. doi: 10.3390/ijms25095012. Int J Mol Sci. 2024. PMID: 38732230 Free PMC article.
-
Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome.Toxins (Basel). 2019 May 15;11(5):275. doi: 10.3390/toxins11050275. Toxins (Basel). 2019. PMID: 31096702 Free PMC article. Review.
-
Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?Annu Rev Neurosci. 2016 Jul 8;39:1-17. doi: 10.1146/annurev-neuro-070815-014038. Epub 2016 Feb 24. Annu Rev Neurosci. 2016. PMID: 27023732 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
